Pharmaline's primary focus area is in formulation development. Headed by a strong pool of scientists and researchers, R&D activities are at the core of our company.
Our development process is carried out using a host of state-of-the-art equipment to support analytical challenges and is applied within ICH guidelines. The process includes: formulation development, testing for strength, safety, efficacy, stability and bioavailability.
Pharmaline's continuing R&D initiatives have strengthened our product portfolio with the delivery of niche, complex, and super-generic products.
Our formulations are adapted to the needs of patients and markets. We produce medicines that are sugar-free, alcohol-free, and colorant-free. The quality of our products meets regulatory requirements and our own rigorous internal standards and specifications.
In line with Pharmaline’s culture, we collaborate with academic institutions and private CROs by conducting bioequivalence studies.
These are carried out in accordance with Good Clinical Practice (GCP) guidelines and ethical standards for Human Experimentation established by the Declaration of Helsinki.
Several of our bioequivalence studies were published in peer -reviewed international journals:
- 1. Bustami R, Khasawneh S, Absi W, Feddah, H, Menassa M, Daccache E, Taha MS, Kyriacos S. Bioequivalence of a Fixed Dose Combination of Desloratadine/Betamethasone Tablets (Oradus Beta) in Healthy Human Volunteers. J Bioequiv Availab 2016; 8(5): 233-241.
- 2. Bustami R, Khasawneh S, Absi W, Feddah, H, Mroueh M, Daccache E, Sarraf JC, Kyriacos S. Bioequivalence of Losartan/Amlodipine Fixed Dose Combination Tablets (Losanet AM) Compared with Concomitant Administration of Single Components of Losartan and Amlodipine Tablets in healthy Human Volunteers. J Bioequiv Availab 2015; 7(5): 216-224.
- 3. Al-Ghazawi A, Idkaidek N, Daccache E, Sarraf JC, Kyriacos S. Bioequivalence of Two Pregabalin 300 mg capsules (Neurexal and Lyrica) in Healthy Human Volunteers. Drug Res 2014; 64:358-362.